Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBI-1901 in Recurrent Glioblastoma
NCT03382977Phase 2Terminated
- Sponsor
- VBI Vaccines Inc.
- Start
- Dec 2017
- Primary completion
- Jul 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of VBI-1901 in glioblastoma (GBM), sponsored by VBI Vaccines Inc.. Started Dec 2017; status: terminated.
02
Drugs
VBI-1901
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03382977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382977.